Abstract
In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 345-355 |
| Number of pages | 11 |
| Journal | Journal of Clinical Lipidology |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2019 |
Fingerprint
Keywords
- Cholesterol guidelines
- Coronary calcium scoring
- Cost value assessment
- Evidence-based medicine
- Lipid clinical practice
- Risk-enhancing factors
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Nutrition and Dietetics
- Cardiology and Cardiovascular Medicine
Cite this
JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines : Process and product. / Braun, Lynne T.; Saseen, Joseph J.; Orringer, Carl Edward; Stone, Neil J.; Guyton, John R.
In: Journal of Clinical Lipidology, Vol. 13, No. 3, 01.05.2019, p. 345-355.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines
T2 - Process and product
AU - Braun, Lynne T.
AU - Saseen, Joseph J.
AU - Orringer, Carl Edward
AU - Stone, Neil J.
AU - Guyton, John R.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.
AB - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.
KW - Cholesterol guidelines
KW - Coronary calcium scoring
KW - Cost value assessment
KW - Evidence-based medicine
KW - Lipid clinical practice
KW - Risk-enhancing factors
UR - http://www.scopus.com/inward/record.url?scp=85067449315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067449315&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2019.05.008
DO - 10.1016/j.jacl.2019.05.008
M3 - Review article
C2 - 31229021
AN - SCOPUS:85067449315
VL - 13
SP - 345
EP - 355
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 3
ER -